Preservative methods for autologous peripheral blood stem cells collected from Thai patients with multiple myeloma
Article Sidebar
Main Article Content
Abstract
Background: Bone marrow transplantation in multiple myeloma patients is one of the methods for multiple myeloma therapy. Blood stem cell preservation is very important for transplant therapy. Thus, preservative methods of peripheral blood stem cells (PBSCs) must be evaluated for successful transplantation.
Objectives: The aim of this study was to collect and preserve autologous peripheral PBSCs (CD34+/CD38-) from multiple myeloma patients at 4°C and deep-freezing.
Materials and methods: PBSCs were collected by leukapheresis before being cryopreserved and kept in liquid nitrogen. The number of CD34+/CD45dim cells were investigated and subpopulation CD34+/CD38- cells were evaluated by trypan blue exclusion method and 7-AAD by flow cytometry before and after cryopreservation.
Results: The result showed that CD34+/CD38- cells constituted 45.08% of total CD34+ cells and 0.56% of total nucleated cells (TNCs). After thawing, CD34+/CD38- cell number did not show significant differences when compared to pre-storage. The CFU recovery after cryopreservation and storage at 4°C for 7 days were 93.53±5.83 and 63.77±12.40%, respectively. Storage at 4°C for 7 days showed significant decrease when compared to day 1. The remaining of total CFU after deep-freezing and storage at 4°C confirmed the tolerant and robust recovery of CD34+/CD38- cells. The engraftments of deep-freezing cells were 100% successful within 11 days without graft failure.
Conclusion: In this present study, we assess the process of storage for high quality and recovery of PBSCs at 4°C within 3 days and cryopreservation for development of autologous hematopoietic stem cell (HSC) transplantation in multiple myeloma patients. Moreover, these conditions are important data guideline for HSC preservations and applications in the future.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Personal views expressed by the contributors in their articles are not necessarily those of the Journal of Associated Medical Sciences, Faculty of Associated Medical Sciences, Chiang Mai University.
References
Cancer incidence in five continents. In: Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al., editors. Cancer incidence in five continents. X. Lyon, France: International Agency for Research on Cancer; 2013. p. 23-36.
The International Agency for Research on Cancer. Cancer by organ site. In: Bernard W. Stewart, Wild CP, editors. World Cancer Report 2014. Lyon, France: The International Agency for Research on Cancer; 2014. p. 482-94.
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335(2): 91-7.
Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106(12): 3755-9.
Kumar L, Ghosh J, Ganessan P, Gupta A, Hariprasad R, Kochupillai V. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. Bone Marrow Transplant 2009; 43(6): 481-9.
Hunt CJ, Armitage SE, Pegg DE. Cryopreservation of umbilical cord blood: 2. Tolerance of CD34+ cells to multimolar dimethyl sulphoxide and the effect of cooling rate on recovery after freezing and thawing. Cryobiology 2003; 46(1): 76-87.
Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5(3): 213-26.
Joint Accreditation Committee - ISCT & EBMT. International standards for cellular therapy product collection, processing and administration 2015. Available from: http://www.ebmt.org.
Donmez A, Yilmaz F, Soyer N, Cagirgan S, Arik B, Tombuloglu M. The loss of CD34+ cells in peripheral hematopoietic stem cell products cryopreserved by non-controlled rate freezing and stored at −80 °C after overnight storage. Transfus Apher Sci 2014; 51(2): 188-92.
Fisher V, Khuu H, David-Ocampo V, Byrne K, Pavletic S, Bishop M, et al. Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation. Transfusion 2014; 54(4): 1088-92.
Valeri CR, Pivacek LE. Effects of the temperature, the duration of frozen storage, and the freezing container on in vitro measurements in human peripheral blood mononuclear cells. Transfusion 1996; 36(4): 303-8.
Liseth K, Abrahamsen JF, Bjorsvik S, Grottebo K, Bruserud O. The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft. Cytotherapy 2005; 7(4): 328-33.
Castelhano MV, Reis-Alves SC, Vigorito AC, Rocha FF, Pereira-Cunha FG, De Souza CA, et al. Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw. Transfus Apher Sci 2013; 48(2): 241-6.
Berens C, Heine A, Muller J, Held SA, Mayer K, Brossart P, et al. Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. Cytotherapy 2016; 18(10): 1325-31.
Antonenas V, Garvin F, Webb M, Sartor M, Bradstock KF, Gottlieb D. Fresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport. Cytotherapy 2006; 8(2): 158-65.
Jansen J, Nolan PL, Reeves MI, Akard LP, Thompson JM, Dugan MJ, et al. Transportation of peripheral blood progenitor cell products: effects of time, temperature and cell concentration. Cytotherapy 2009; 11(1): 79-85.
Kao GS, Kim HT, Daley H, Ritz J, Burger SR, Kelley L, et al. Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. Transfusion 2011; 51(1): 137-47.
Suzuki T, Muroi K, Tomizuka H, Amemiya Y, Miura Y. Characterization of enriched CD34+ cells from healthy volunteers and those from patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF). Stem Cells 1995; 13(3): 273-80.
Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404(6774): 193-7.
Morgenstern DA, Ahsan G, Brocklesby M, Ings S, Balsa C, Veys P, et al. Post-thaw viability of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes. Br J Haematol 2016; 174(6): 942-51.
Shima T, Iwasaki H, Yamauchi T, Kadowaki M, Kiyosuke M, Mochimaru T, et al. Preserved in vivo reconstitution ability of PBSCs cryopreserved for a decade at -80 °C. Bone Marrow Transplant 2015; 50(9): 1195-200.
Sartor M, Antonenas V, Garvin F, Webb M, Bradstock K. Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant 2005; 36(3): 199-204.
Makino S, Harada M, Akashi K, Taniguchi S, Shibuya T, Inaba S, et al. A simplified method for cryopreservation of peripheral blood stem cells at -80 degrees C without rate-controlled freezing. Bone Marrow Transplant 1991; 8(4): 239-44.
Scerpa MC, Daniele N, Landi F, Caniglia M, Cometa AM, Ciammetti C, et al. Automated washing of human progenitor cells: evaluation of apoptosis and cell necrosis. Transfus Med 2011; 21(6): 402-7.
Reich-Slotky R, Colovai AI, Semidei-Pomales M, Patel N, Cairo M, Jhang J, et al. Determining post-thaw CD34+ cell dose of cryopreserved haematopoietic progenitor cells demonstrates high recovery and confirms their integrity. Vox Sang 2008; 94(4): 351-7.
Pasha R, Elmoazzen H, Pineault N. Development and testing of a stepwise thaw and dilute protocol for cryopreserved umbilical cord blood units. Transfusion 2017; 57(7): 1744-54.
Woods EJ, Perry BC, Hockema JJ, Larson L, Zhou D, Goebel WS. Optimized cryopreservation method for human dental pulp-derived stem cells and their tissues of origin for banking and clinical use. Cryobiology 2009; 59(2): 150-7.
Spurr EE, Wiggins NE, Marsden KA, Lowenthal RM, Ragg SJ. Cryopreserved human haematopoietic stem cells retain engraftment potential after extended (5–14 years) cryostorage. Cryobiology 2002; 44(3): 210-7.
Ikebuchi K. [Hemopoietic colony formation in semisolid and liquid culture system]. Rinsho Byori 1995; Suppl 99: 123-35.
Wolff S. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002; 29(7): 545-52.
Teltschik HM, Heinzelmann F, Gruhn B, Feuchtinger T, Schlegel P, Schumm M, et al. Treatment of graft failure with TNI‐based reconditioning and haploidentical stem cells in paediatric patients. Br J Haematol 2016; 175(1): 115-22.